Bausch Health Companies Inc.
Financials
Valuation Metrics
Bausch Health Companies Inc.'s Market Cap is $2.11B. At end of 2025 it was $2.58B. Ranked #1987 of 3,121 in US market (top 64%), #1232 of 1,658 on NYSE (top 74%), #134 of 266 in Pharmaceuticals, Biotechnology & Life Sciences (top 50%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.11B | US#1,987/3,121 Sec#134/266 |
| Revenue | $10.85B | US#534/3,121 Sec#19/266 |
| Net Income | $-1.10B | US—/3,121 Sec—/266 |
| Total Assets | $24.79B | US#540/3,121 Sec#21/266 |
| Net Assets | $-1.77B | US#3,063/3,121 Sec#266/266 |
| Employees | 20,300 | US#545/3,121 Sec#19/266 |
| Value | ||
| P/S | 0.19x | US#88/3,121 Sec#1/266 |
| EV/EBITDA | 10.29x | US#857/3,121 Sec#26/266 |
| FCF Yield | 65.93% | US#17/3,121 Sec#1/266 |
| Profitability | ||
| ROA | -4.43% | US#2,500/3,121 Sec#86/266 |
| Op. Margin | 25.44% | US#674/3,121 Sec#32/266 |
| Revenue Growth | 10.09% | US#1,261/3,121 Sec#99/266 |
| Earnings Growth | -1220.41% | US#2,036/3,121 Sec#70/266 |
| Financial Health | ||
| Total Debt | $20.78B | US#227/3,121 Sec#15/266 |
| FCF | $1.39B | US#474/3,121 Sec#23/266 |
| Cash | $1.82B | US#439/3,121 Sec#20/266 |
| Current Ratio | 1.44x | US#1,741/3,121 Sec#241/266 |
| Net Debt/EBITDA | 9.26x | US#2,342/3,121 Sec#82/266 |
| Performance | ||
| 1Y Return | -17.20% | US#2,333/3,121 Sec#207/266 |
| 1M Return | -18.40% | US#2,932/3,121 Sec#235/266 |
| From 52W High | -29.31% | US#2,028/3,121 Sec#159/266 |
| 1Y MDD | -43.92% | US#2,209/3,121 Sec#159/266 |
| Trading | ||
| Volume | 1,987,001 shares | US#829/3,121 Sec#84/266 |
| Trading Value | $11M | US#2,272/3,121 Sec#185/266 |
| Per Share | ||
| EPS | $-2.94 | US—/3,121 Sec—/266 |
| BPS | $-4.74 | US—/3,121 Sec—/266 |
Company Info
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.